title: Comparison of famciclovir and lamivudine in the long-term treatment of hepatitis B infection after liver transplantation.
abstract: BACKGROUND
  Preliminary results of short-term famciclovir and lamivudine therapy in patients with hepatitis B virus (HBV) infection after liver transplantation revealed promising results. In a retrospective study the efficacy of long-term treatment with these substances was compared.
  
  
  METHODS
  A total of 53 HBV-infected adults (48 reinfections and 7 de novo infections) received antiviral treatment. A total of 32 of these patients were treated with famciclovir 3x500 mg, 20 of them were later switched to lamivudine. Fourteen patients received lamivudine, 150 mg/day orally, as first line therapy and 7 patients after failure of famciclovir-prophylaxis. Follow-up time was 8 to 62 months (mean 35 months). Response to therapy (HBV-DNA negative) was compared using Kaplan-Meier estimates. Potential influence factors (HBV-DNA and HBeAg pretransplant, HDV coinfection, pretreatment with famciclovir and immunosuppression) on treatment response were analyzed by log. Rank test (univariate); then a multivariate analysis (Cox multiple stepwise regression model) was applied.
  
  
  RESULTS
  A total of 19 and 76% of the patients treated with famciclovir and lamivudine resp. became HBV-DNA negative; 0 and 24% HBsAg negative. Lamivudine was also effective as second line therapy. In a multivariate analysis of all 73 treatment courses, lamivudine treatment and HDV-coinfection were significant factors for better treatment response; regarding only the lamivudine group, negative HBeAg pretransplant was significant. Viral breakthrough after prolonged treatment occurred in 55% (lamivudine) to 80% (famciclovir) of treatment courses but was only accompanied by mild hepatitis.
  
  
  CONCLUSIONS
  Lamivudine and famciclovir are potent drugs for the treatment of HBV-infection after liver transplantation. The antiviral capacity of lamivudine is superior even after pretreatment with famciclovir but after prolonged treatment viral breakthrough is often observed.
authors.affiliation: Department of Surgery, Humboldt University, Berlin, Germany.
authors.forename: N
authors.initials: N
authors.lastname: Rayes
authors.forename: D
authors.initials: D
authors.lastname: Seehofer
authors.forename: U
authors.initials: U
authors.lastname: Hopf
authors.forename: R
authors.initials: R
authors.lastname: Neuhaus
authors.forename: U
authors.initials: U
authors.lastname: Naumann
authors.forename: W O
authors.initials: WO
authors.lastname: Bechstein
authors.forename: P
authors.initials: P
authors.lastname: Neuhaus
mesh_terms: D015075:2-Aminopurine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D004279:DNA, Viral / Q000097:blood; D000077595:Famciclovir; D005260:Female; D006509:Hepatitis B / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D006515:Hepatitis B virus / Q000235:genetics; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D016031:Liver Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D013997:Time Factors
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D019259:Lamivudine; D015075:2-Aminopurine; D000077595:Famciclovir